Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens

Table 1

Frequency of autoantibodies against 15 TAAs in prostate cancer and BPH.

Conditions

𝑁

cyclin B1

IMP1

Koc

p62

p90

p53

survivin

RalA

p16

CAPERα

14-3-3 ζ

MDM2

NPM1

c-Myc

DFS70

PCa

174

54; (31.0)^∆

8; (4.6)

15; (8.6)

8; (4.6)

16; (9.2)

34; (19.5)^∆

35; (20.1)^∆

30; (17.2)^∆

14; (8.0)

7; (4.0)

4; (2.3)

27; (15.5)^∆

18; (10.3)*

6; (3.4)

30; (17.2)^∆

NHS

89

2; (2.2)

3; (3.4)

2; (2.2)

2; (2.2)

3; (3.4)

1; (1.1)

1; (1.1)

2; (2.2)

2; (2.2)

0; (0.0)

0; (0.0)

1; (1.1)

2; (2.2)

1; (1.1)

3; (3.4)

BPH

21

1; (4.8)

1; (4.8)

0; (0.0)

2; (9.5)

1; (4.8)

2; (9.5)

0; (0.0)

2; (9.5)

0; (0.0)

2; (9.5)

0; (0.0)

2; (9.5)

1; (4.8)

2; (9.5)

2; (9.5)

SLE

51

3; (5.9)

2; (3.9)

2; (3.9)

2; (3.9)

3; (5.9)

0; (0.0)

2; (3.9)

2; (3.9)

2; (3.9)

2; (3.9)

1; (2.0)

2; (3.9)

3; (5.9)

2; (3.9)

1; (2.0)

PSS

94

3; (3.2)

1; (1.1)

0; (0.0)

0; (0.0)

2; (2.1)

3; (3.2)

4; (4.3)

2; (2.1)

2; (2.1)

0; (0.0)

3; (3.2)

3; (3.2)

2; (2.1)

0; (0.0)

2; (2.1)

PCa: prostate cancer, NHS: normal human serum, BPH: benign prostatic hyperplasia, SLE: systemic lupus erythematosus, and PSS: progressive systemic sclerosis.
^▵𝑃<0.01 compared to NHS.
^∗𝑃<0.05 compared to NHS.